Pretransplant HCV clearance and prevention of post-transplant HCV-related glomerulonephritis

Pretransplant HCV clearance and prevention of post-transplant HCV-related glomerulonephritis is a preventive strategy built around a crucial distinction: anti-HCV positivity records exposure, whereas detectable HCV RNA identifies active infection. In kidney-transplant candidates, eliminating active hepatitis C virus infection before transplantation can protect the renal allograft from HCV-related glomerular lesions and avoids the hazards of treating an established infection after transplantation, when interferon may provoke acute rejection and graft loss.

Definition and Clinical Rationale

The relationship arises from the systemic nature of hepatitis C. HCV is not confined to the liver; it can produce renal and immune-mediated disease, including HCV-related glomerulopathy. In native kidneys, membranoproliferative glomerulonephritis, particularly when associated with type II cryoglobulinemia, is the predominant recognized pattern, while other reported lesions include membranous glomerulonephritis, focal segmental glomerular sclerosis, proliferative glomerulonephritis, fibrillary and immunotactoid glomerulopathies, IgA nephropathy, rapidly progressive glomerulonephritis, and thrombotic microangiopathy. After kidney transplantation, the same infection can injure a new kidney through de novo disease, making viral clearance before transplantation more than a virologic endpoint: it is an attempt to remove a continuing renal threat before immunosuppression begins.

The diagnostic threshold is correspondingly specific. Chronic infection is established by the combination of anti-HCV antibodies and HCV RNA in serum; absence of RNA indicates recovery or clearance rather than merely a negative antibody test. This distinction determines who requires antiviral treatment and who can be regarded as virologically cleared before receiving an allograft. Because patients with end-stage renal disease may have advanced liver injury as well as renal complications, transplant evaluation also requires staging of liver disease. Studies cited in the transplant literature found advanced stage 3 or 4 liver injury, including cirrhosis, in 10–25% of candidates who underwent biopsy, and liver biopsy remained the reference standard when active infection was identified.

Antiviral Therapy Before Transplantation

For HCV-positive, HCV RNA-positive dialysis patients who are candidates for kidney transplantation, the preventive approach is to attempt eradication before the operation. The therapies discussed in the evidence include interferon alone or interferon combined with ribavirin; in the broader treatment landscape, pegylated interferon and ribavirin achieved sustained virologic response in more than half of patients with chronic infection, while newer direct-acting antiviral drugs were being developed to improve response, especially in genotype 1 infection. In the dialysis population specifically, antiviral treatment produced HCV clearance in approximately 50% of patients.

The timing is clinically decisive. Interferon-based treatment after transplantation is associated with an increased risk of renal-allograft rejection, and most clinicians therefore avoid interferon in kidney-transplant recipients. Ribavirin has been used in some settings, but renal insufficiency can cause hemolytic anemia, and ribavirin monotherapy cannot produce sustained virologic response. Treatment before transplantation places the toxicities of antiviral therapy—flu-like symptoms, fatigue, headache, myalgia, arthralgia, anemia, neutropenia, depression, and anxiety—against a safer immunologic setting, even though these adverse effects can lead to dose reduction in 35–42% of patients and treatment discontinuation in about 30%.

The preventive rationale also reflects the expected longevity of transplant candidates. KDIGO guidance recommended treatment for HCV-positive kidney-transplant candidates because their life expectancy is greater than that of many patients who remain on dialysis, while immunosuppression can accelerate liver disease and post-transplant interferon can threaten graft function. There is not complete agreement about treating every patient with active viremia before transplantation, and evidence that pretransplant sustained virologic response slows all later liver injury remains limited. Nevertheless, the risk of post-transplant renal disease and the difficulty of treating HCV after transplantation make pretransplant clearance the preferred opportunity for eradication.

Evidence for Protection of the Allograft

The clearest evidence for the relationship comes from comparison of transplant recipients who remained HCV RNA-negative before transplantation with those who entered transplantation while still viremic. Dialysis patients who became HCV RNA-negative before kidney transplantation developed significantly less HCV-related glomerulonephritis after transplantation. The protective observation is strengthened by the absence of relapse or occult HCV infection in these cleared patients despite heavy immunosuppression, including lymphocyte-depleting agents. Clearance therefore appears to persist through the very treatment environment that would otherwise be expected to intensify viral replication.

The contrast is clinically important because recipients who undergo transplantation while HCV RNA-positive remain exposed to several forms of injury. HCV infection may impair patient and allograft survival and can produce liver dysfunction, fibrosing cholestatic hepatitis, cirrhosis, and eventually hepatocellular carcinoma. Within the kidney allograft, reported complications include de novo HCV-related glomerulopathy, acute and chronic transplant glomerulopathy, and renal thrombotic microangiopathy associated with anticardiolipin antibodies. The prevention of post-transplant HCV-related glomerulonephritis thus belongs to a wider effort to prevent both renal and hepatic consequences of persistent viremia under immunosuppression.

The proposed mechanism is local as well as systemic. Even when circulating immune-complex levels are low, the renal allograft may express more proinflammatory cytokines than a native kidney. Inflammatory stimulation can increase Toll-like receptor 3 expression in mesangial cells; HCV double-stranded RNA may bind to that receptor, amplify local inflammation, promote chemokine and cytokine production, recruit mononuclear cells, and contribute to mesangial apoptosis and membranoproliferative glomerulonephritis. Pretransplant clearance interrupts this sequence before viral material and the immunosuppressed inflammatory environment can act on the allograft.

Post-Transplantation Management and Significance

Once HCV-related glomerulonephritis has developed after transplantation, treatment is mainly symptomatic and preventive evidence is stronger than therapeutic evidence. No specific immunosuppressant has been established as clearly protective or harmful in this setting. Interferon is generally avoided because of the danger of acute rejection and graft loss. Ribavirin may be considered in selected circumstances, but its anemia risk is substantial in renal insufficiency and it cannot sustain viral eradication alone. Rituximab has produced disappearance of cryoglobulinemia and glomerular subendothelial immune deposits in reported cases, yet it can cause overimmunosuppression and may increase viral replication.

The practical consequence is a sequence of screening, staging, treatment, and surveillance. Candidates should be screened for anti-HCV and active viremia, and those with active infection should undergo liver assessment; established or decompensated cirrhosis may require referral for consideration of simultaneous liver–kidney transplantation rather than kidney transplantation alone. Patients who achieve sustained virologic response before transplantation should undergo at least annual nucleic-acid testing to confirm durability, while those who remain viremic require regular reassessment of liver disease during sometimes prolonged waiting periods. In this framework, pretransplant HCV clearance is not simply an earlier version of post-transplant treatment. It is the point at which viral eradication can preserve the future graft without exposing that graft to interferon-associated rejection, and the evidence supports prevention as the most reliable defense against HCV-related glomerular disease after kidney transplantation.